The expression levels of RIPK1, RIPK3, MLKL, CASP8, TNF, CASP6, TRPM7, FADD, PELI1, PGLYRP1, TNIP1, TP53, TNFRSF1A, BIRC2, MEFV, AIM2, TNFAIP3, SERTAD1, TRAF2, NFKB1, CFLAR, FAS, GSK3B, TRADD, and TLR3 were significantly enhanced in AD samples, whereas that of CYLD, ITPK1, MAP3K7, SPATA2, SIRT3, HMGB1, UCHL1, CTSB, MAPK14, SFTPA1, and FASLG were downregulated in AD samples (Figure 2A), and a heatmap displaying the disparate expression levels of such differentially expressed NRGs between postmortem brain of patients with AD and ND was constructed (Figure 2B). This evidence concerns the gene RIPK3 and Alzheimer disease.